Testing a diabetes drug to lessen lung cancer treatment side effects
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a medicine typically used for diabetes or weight loss (a GLP-1 drug) can help reduce side effects from the lung cancer drug lorlatinib. If you are already taking lorlatinib for your ALK-positive lung cancer and have not used a GLP-1 drug recently, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are already taking lorlatinib for your ALK-positive lung cancer as your first treatment.
- You have not used a GLP-1 drug (like Ozempic, Wegovy, or Mounjaro) in the past 3 months.
- You are not currently taking other weight-loss medications or certain diabetes drugs (DPP-4 inhibitors like Januvia) in the past month.
- You have no history of pancreatitis, thyroid cancer, or a condition called multiple endocrine neoplasia type 2.
- You are not pregnant, breastfeeding, or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the safety of dapagliflozin (a diabetes drug) taken before surgery for stage IA lung adenocarcinoma. It may help understand if this drug can slow tumor growth while waiting for surgery.
This study tests whether a GLP-1 medication (a type of drug that helps with weight and blood sugar) can improve lung function and muscle strength in people with COPD who are overweight or have weight-related health problems. It may offer a new way to treat both breathing and muscle issues in COPD.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study tests if the targeted drug lorlatinib works better than the usual combination of chemotherapy and radiation for people with a specific type of advanced lung cancer that has a change in the ALK gene. It aims to shrink tumors and stop them from growing.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
This trial tests the drug lorlatinib given before surgery to shrink tumors in people with a specific genetic change (ALK rearrangement) in their lung cancer. It may help make surgery more effective.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.